{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:00Z","timestamp":1793424720266,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.016","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:37:20Z","timestamp":1792021040000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Stem Cell-based Flow Cytometry Assay to Predict Post-transplantation Relapse in Patients With Myelodysplastic Syndromes With Excess Blasts: A Prospective Study"],"prefix":"10.1016","author":[{"given":"Wei-Bing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Fei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Su","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jtct.2026.10.016_bib0001","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic Syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.016_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.jtct.2026.10.016_bib0003","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0004","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.016_bib0005","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/leu.2016.110","article-title":"Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant","volume":"30","author":"Wang","year":"2016","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.jtct.2026.10.016_bib0006","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.016_bib0007","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.016_bib0008","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jtct.2026.10.016_bib0009","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/bloodadvances.2023010098","article-title":"Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes","volume":"7","author":"Schulz","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.jtct.2026.10.016_bib0010","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cncr.34762","article-title":"Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: a multicenter, retrospective cohort study","volume":"129","author":"Ma","year":"2023","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0011","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/leu.2015.252","article-title":"A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0012","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41375-024-02148-3","article-title":"Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR","volume":"38","author":"Klyuchnikov","year":"2024","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.jtct.2026.10.016_bib0013","first-page":"2657","article-title":"Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial","volume":"141","author":"Ngai","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.016_bib0014","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.016_bib0015","first-page":"2942","article-title":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","volume":"110","author":"Ngai","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.016_bib0016","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","article-title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","volume":"25","author":"Chen","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.016_bib0018","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41375-023-01811-5","article-title":"Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression","volume":"37","author":"van Spronsen","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.016_bib0019","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","article-title":"Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study","volume":"13","author":"Chang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2026.10.016_bib0021","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0022","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN Guidelines(R) Insights: myelodysplastic Syndromes, Version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.016_bib0023","doi-asserted-by":"crossref","first-page":"E659","DOI":"10.1002\/ajh.24910","article-title":"Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts","volume":"92","author":"Chang","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0024","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/joim.13535","article-title":"Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia","volume":"292","author":"Woll","year":"2022","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.016_bib0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"7633","key":"10.1016\/j.jtct.2026.10.016_bib0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0027","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","article-title":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13059-023-03031-7","article-title":"Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML","volume":"24","author":"Zhang","year":"2023","journal-title":"Genome Biol"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.016_bib0029","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","article-title":"NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome","volume":"107","author":"Braun","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.10.016_bib0030","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood.2020009023","article-title":"A JAK\/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML","volume":"137","author":"Chen","year":"2021","journal-title":"Blood"},{"issue":"7570","key":"10.1016\/j.jtct.2026.10.016_bib0031","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"issue":"800","key":"10.1016\/j.jtct.2026.10.016_bib0032","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.add7705","article-title":"IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways","volume":"16","author":"Naef","year":"2023","journal-title":"Sci Signal"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.016_bib0033","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41556-020-0507-y","article-title":"Overcoming Wnt-beta-catenin dependent anticancer therapy resistance in leukaemia stem cells","volume":"22","author":"Perry","year":"2020","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0034","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12967-024-05165-z","article-title":"Single-cell transcriptomics dissects the transcriptome alterations of hematopoietic stem cells in myelodysplastic neoplasms","volume":"22","author":"Zeng","year":"2024","journal-title":"J Transl Med"},{"issue":"34","key":"10.1016\/j.jtct.2026.10.016_bib0035","article-title":"Stabilization of TGF-beta receptor 1 by a receptor-associated adaptor dictates feedback activation of the TGF-beta signaling pathway to maintain liver cancer stemness and drug resistance","volume":"11","author":"Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0036","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230279","article-title":"Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL","volume":"221","author":"Fregona","year":"2024","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0037","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41421-024-00654-3","article-title":"RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation","volume":"10","author":"Lin","year":"2024","journal-title":"Cell Discov"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2006.05.025","article-title":"STAT1 acts as a tumor promoter for leukemia development","volume":"10","author":"Kovacic","year":"2006","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109386","article-title":"TNF-alpha-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling","volume":"36","author":"Agarwal","year":"2021","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.jtct.2026.10.016_bib0040","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1096\/fj.201900099R","article-title":"Leukemic IL-17RB signaling regulates leukemic survival and chemoresistance","volume":"33","author":"Guo","year":"2019","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.016_bib0041","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/0008-5472.CAN-14-3625","article-title":"SOCS2 controls proliferation and stemness of hematopoietic cells under stress conditions and its deregulation marks unfavorable acute leukemias","volume":"75","author":"Vitali","year":"2015","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.016_bib0042","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41375-023-01880-6","article-title":"Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation","volume":"37","author":"Lu","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.016_bib0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.stem.2021.12.007","article-title":"TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity","volume":"29","author":"Muto","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.016_bib0044","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.016_bib0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cyto.b.22148","article-title":"Flow cytometric analysis of CD34(+) CD38(-) cells; cell frequency and immunophenotype based on CD45RA expression pattern","volume":"106","author":"Mizuta","year":"2024","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.016_bib0046","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:59:36Z","timestamp":1793422776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S2666636726008067"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Stem Cell-based Flow Cytometry Assay to Predict Post-transplantation Relapse in Patients With Myelodysplastic Syndromes With Excess Blasts: A Prospective Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}